Table 1.
Studies selected for meta-analysis
| Study | Year | Number of patients | Method | Sensitivity of method (%) | Specimen | Histology | T790M mutation, n (%) |
|---|---|---|---|---|---|---|---|
| Fujita et al19 | 2012 | 35 | CH | 0.01 | Surgery | AD | 28 (80) |
| Maheswaran et al20 | 2008 | 26 | SARMs assay | 0.1 | Biopsy | AD | 10 (38.46) |
| Rosell et al18 | 2011 | 129 | TaqMan® assay | 0.02 | Biopsy | AD | 45 (34.88) |
| Su et al21 | 2012 | 56 | MALDI-TOF MS | 0.4 | Biopsy | AD (94.3%) SQ (5.7%)* | 23 (41.07) |
Note:
*
The percentage of 88 patients including 56 activating epidermal growth factor receptor-positive patients.
Abbreviations: AD, adenocarcinoma; CH, colony hybridization; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; SARMs, selective androgen-receptor modulators; SQ, squamous-cell carcinoma.